Ezutromid

• Description :

  Ezutromid (SMT C1100) is a first-in-class, orally active benzoxazole utrophin modulator with an EC50 of 0.91 μM. Ezutromid can be used for the research Duchenne muscular dystrophy (DMD) . Ezutromid inhibits CYP1A2 enzymic activity in human liver microsomes (HLM) with an IC50 of 5.4 μM[1][2].

• CAS Number :

  [945531-77-1]

• Product Name Alternative :

  SMT C1100; BMN 195; VOX-C1100

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319

• Target :

  Cytochrome P450

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Others

• Assay Protocol :

  https://www.medchemexpress.com/Ezutromid.html

• Purity :

  98.94

• Solubility :

  DMSO : 10 mg/mL (ultrasonic; warming)

• Smiles :

  O=S(C1=CC=C(OC(C2=CC=C3C=CC=CC3=C2)=N4)C4=C1)(CC)=O

• Molecular Formula :

  C19H15NO3S

• Molecular Weight :

  337.39

• Precautions :

  H315, H319

• References & Citations :

  [1]Tinsley JM et al. Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS One. 2011 May 6;6 (5) :e19189.|[2]Tinsley J et al. Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to healthy male adult volunteers. J Clin Pharmacol. 2015 Jun;55 (6) :698-707.|[3]Guiraud S et al. Second-generation compound for the modulation of utrophin in the therapy of DMD. Hum Mol Genet. 2015 Aug 1;24 (15) :4212-24.|[4]Chancellor DR, et al. Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of Duchenne muscular dystrophy. J Med Chem. 2011;54 (9) :3241-3250.|[5]Chatzopoulou M, et al. Isolation, Structural Identification, Synthesis, and Pharmacological Profiling of 1,2-trans-Dihydro-1,2-diol Metabolites of the Utrophin Modulator Ezutromid. J Med Chem. 2020;63 (5) :2547-2556.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  CYP1